-The Indian Express Report finds govt did not recover dues of Rs 750 cr from distributors. At a time when the opposition BJP plans to intensify protests against power tariff in Delhi, the Comptroller and Auditor General (CAG) of India's report for the 2011-12 fiscal has slammed the Delhi government for not recovering dues to the tune of Rs 750 crore from private distribution companies. The report, tabled on Tuesday in the Delhi...

-The Business Standard CAG state audit report NCT has also unearthed a glaring lack of planning cutting across projects, sectors It may be India's capital city, but behind the New Delhi's storied corridors of power and flush coffers, the metropolis is a difficult mess for the ordinary citizen. The Comptroller and Auditor General's (CAG) state audit report for the National Capital Territory (NCT) of Delhi government has unearthed a series of significant shortcoming...

-The Business Standard Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG's patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker. This is because the judgement...

-The Hindu   It joins hands with AIIMS to offer health services to villagers Raipur: Maoists as well as security forces have hit upon new strategies to gain an upper hand in the ongoing conflict. The latest one - to check the influence of rebels - has come from the Central Reserve Police Force (CRPF). It is not at all a military manoeuvre, but an offer of medical assistance to villagers in the Maoist-controlled...

-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...